Circio Holding ASA

Circular RNA innovator Circio to present strengthened circVec gene therapy data at ASGCT 2025

· Circio will present new and strengthened circVec in vivo proof-of-concept data

at the American Society of Gene and Cell Therapy (ASGCT) annual meeting

· The poster presentation will take place on 13 May 2025 in New Orleans, USA

· ASGCT is considered the most prestigious and widely attended international

conference in the gene and cell therapy field

Oslo, Norway 6 May 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology

company developing powerful circular RNA technology for next generation nucleic

acid medicine, today announces that it will present new and strengthened circVec

circular RNA in vivo data at the American Society of Gene and Cell Therapy

(ASGCT) annual meeting 2025 taking place in New Orleans, USA, 13-17 May 2025.

In the poster presentation, Circio will showcase the latest in vivo results for

the circVec synthetic DNA and AAV gene therapy platform. circVec circular RNA

-based vectors have the potential to substantially boost protein expression

level and durability for both viral and non-viral gene and cell therapy.

Recently generated in vivo data further validates and strengthens the circVec

system in specific settings, and provides important context to prioritize

development areas and partnering strategy.

Title of presentation:

CircVec: a powerful circular RNA expression platform to enhance viral and non

-viral gene and cell therapies

Time and poster number:

13 May 2025, 18:00-19:30hrs CDT, poster #655

Location:

Ernest N. Morial Convention Center, New Orleans, Louisiana, USA

The poster will be made available on Circio´s webpage (http://www.circio.com/)

after the presentation

AI Terminal